Crossmark

Aspirin use is associated with improvement in distant metastases outcome in patients with residual disease after neoadjuvant chemotherapy

Crossref DOI link: https://doi.org/10.1007/s10549-023-06920-4

Published Online: 2023-03-30

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johns, Christopher https://orcid.org/0000-0001-7589-7279
Montalvo, Steven K. https://orcid.org/0000-0003-1519-2829
Cauble, M’Kay https://orcid.org/0000-0002-6560-8434
Liu, Yu-Lun https://orcid.org/0000-0003-3541-1814
All, Sean https://orcid.org/0000-0002-2277-2226
Rahimi, Asal S. https://orcid.org/0000-0002-2762-5049
Alluri, Prasanna G. https://orcid.org/0000-0001-7517-9525
Leitch, Marilyn https://orcid.org/0000-0001-6959-0078
Unni, Nisha https://orcid.org/0000-0003-1549-4720
Wooldridge, Rachel https://orcid.org/0000-0003-4840-2829
Farr, Deborah https://orcid.org/0000-0003-0571-3811
Nwachukwu, Chika https://orcid.org/0000-0001-9732-9352
Kim, D. W. Nathan https://orcid.org/0000-0002-4450-3318
License Information

Text and Data Mining valid from 2023-03-30

Version of Record valid from 2023-03-30
More Information

Article History

Received: 12 December 2022

Accepted: 17 March 2023

First Online: 30 March 2023

Declarations

:

: The authors have no relevant financial interests to disclose. Non-financial interests: Dr. Unni has served on advisory boards for Pfizer, Eli Lilly, Novartis, Macrogenics, Biotheranostics, and Eisai.